Sefaxersen significantly cut a key marker of kidney damage in a rare disease that has suddenly attracted a wave of new treatments — and Roche is betting a once-monthly, at-home injection can stand out.
An FDA advisory panel voted that the benefits of Grail’s Galleri outweigh its risks — but a split vote on effectiveness, and a missed goal in a major UK trial, show how much is still unsettled.
A plain-language guide to Berger’s disease — what goes wrong in the kidneys, how it is found, why it is more serious than once thought, and how a wave of new drugs has changed treatment.
In a rare joint letter, the chairs of Europe’s biggest drugmakers say the continent’s share of pharmaceutical research and investment is sliding — and urge governments to act before the decline becomes permanent.
Basecamp Research trained a biological “foundation model” on the world’s largest proprietary gene dataset — and wants to use it to design therapies that reprogram a patient’s own cells inside the body.
The deal for a preclinical radioligand therapy deepens Novartis’s lead in targeted radioactive cancer treatment — and adds to a rush of Western pharma licensing innovative assets from China.
A quiet FDA rule change — letting bone-density scans stand in for fractures in trials — is reigniting drugmaker and investor interest in a common disease that had fallen out of fashion.
Envisagenics uses machine learning to mine “RNA splicing” — a largely untapped source of cancer targets — and Boehringer Ingelheim is paying up to $1 billion to turn those targets into precision therapies.
Dazodalibep met its main targets in a Phase 3 trial for Sjögren’s — the autoimmune disease that dries out eyes and mouths for up to 4 million Americans and has never had an FDA-approved therapy.
A new report finds the American cancer death rate has dropped by more than a third over three decades — the result of less smoking, earlier detection and better treatment — even as new challenges loom.
PET imaging found long-COVID patients have fewer healthy dopamine-releasing neurons in key brain regions — a possible biological explanation for the fatigue, sluggishness and memory problems, and a target for treatment.
Veterans who came off GLP-1 medications faced a rising risk of heart attack, stroke and death — up 22% after two years — suggesting the drugs’ cardiovascular protection fades fast once you stop.